Strategic Partners A/S
F:1TB0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Strategic Partners A/S
F:1TB0
|
DK |
Intrinsic Value
The intrinsic value of 
Strategic Partners A/S (1TB0) under the Base Case is 22.19 EUR per share.
Compared with the current market price of 87 EUR, the stock appears
Overvalued by 74% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Strategic Partners A/S Does
Strategic Partners A/S is a biopharmaceutical company, which engages in the research and development of treatments for rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases.
- Headquarters
- Denmark DK
- Employees
- 1
- IPO date
- Nov 17, 2017
Earnings Waterfall
Strategic Partners A/S
The intrinsic value for Strategic Partners A/S (1TB0) under the Base Case is 22.19 EUR.
Compared with the current market price of 87 EUR, the stock appears Overvalued by 74% .